Seres Therapeutics Inc Cash Flow-to-Debt Ratio
Seres Therapeutics Inc cash flow-to-debt ratio. Seres Therapeutics Inc (MCRB) has a Cash Flow-to-Debt Ratio of -0.33x as of June 2026, meaning its operating cash flow of $-22.39 Million could theoretically repay 0% of its total liabilities ($67.05 Million) in one year. Check Seres Therapeutics Inc (MCRB) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Seres Therapeutics Inc (2012–2025)
Cash flow-to-debt ratio of Seres Therapeutics Inc from 2012 to 2025. Historical debt coverage capacity for Seres Therapeutics Inc across 14 annual periods. Check Seres Therapeutics Inc (MCRB) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Seres Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2012–2025)
Seres Therapeutics Inc cash flow-to-debt ratio by year from 2012 to 2025. Year-by-year debt coverage analysis for Seres Therapeutics Inc. For the full cash flow conversion analysis, see MCRB cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $1.12 Million | $93.97 Million | ▲ +101.0% |
| 2024 | -1.18x | $-148.61 Million | $126.03 Million | ▼ -305.4% |
| 2023 | -0.29x | $-117.35 Million | $403.46 Million | ▲ +57.0% |
| 2022 | -0.68x | $-228.82 Million | $338.00 Million | ▼ -2360.8% |
| 2021 | 0.03x | $6.69 Million | $223.35 Million | ▲ +105.4% |
| 2020 | -0.56x | $-93.61 Million | $168.19 Million | ▼ -31.5% |
| 2019 | -0.42x | $-76.52 Million | $180.76 Million | ▼ -13.5% |
| 2018 | -0.37x | $-62.85 Million | $168.52 Million | ▲ +36.4% |
| 2017 | -0.59x | $-75.52 Million | $128.82 Million | ▼ -286.9% |
| 2016 | 0.31x | $43.92 Million | $140.01 Million | ▲ +108.8% |
| 2015 | -3.55x | $-40.84 Million | $11.51 Million | ▼ -4837.3% |
| 2014 | -0.07x | $-10.36 Million | $144.07 Million | ▲ +98.0% |
| 2013 | -3.56x | $-5.32 Million | $1.49 Million | ▲ +78.3% |
| 2012 | -16.43x | $-2.92 Million | $178.00K | — |